Over the period 2022-2028, the Dengue Vaccines Market is expected to grow at a healthy rate. Analysis of Covid-19
The Dengue Vaccines market is projected to grow at a healthy rate over 2022-2028. Covid-19, the most advanced vaccine candidate against dengue fever, is expected to contribute significantly to this growth. In addition, the market is also projected to benefit from increasing investments in R&D and aggressive marketing campaigns by various stakeholders.
The global dengue vaccine market was valued at US$ 3.4 billion in 2019, and it is anticipated to reach US$ 4 billion by 2024. The dengue vaccine market is dominated by the Asia Pacific region, with a 70.2% share in terms of value. However, the continent is also home to Latin America, where the market is expected to grow moderately. The market’s major challenges include the inability to distinguish dengue fever from other febrile diseases. Moreover, the lack of specific animal models for research and development is another hindrance.
Dengue vaccine Market Growth
The Dengue Vaccines market is segmented into different regions and companies. The regional and type segments are further analyzed in the report. The forecasts include the revenues and volume of the market in each area. The global dengue vaccines market is expected to reach USD million by 2027. The regional market is expected to grow at a CAGR of % between 2018 and 2027.
Several vaccines are under trial for dengue prevention. The Sanofi-developed Dengvaxia is the only one currently commercially available. Takeda’s TAK-003 recently reported encouraging top-line results in a large Phase III clinical trial. Further, the study examines the performance of each of the regions and forecasts the market sizes for all segments.
The global dengue vaccines market is predicted to experience rapid growth due to increasing dengue outbreaks in urban areas over the next few years. According to the Center for Information Technology, Bruno Kessler Foundation, dengue has spread to a non-endemic metropolis in Brazil. In Cairns, Australia, 95% of transmission events occurred within the metropolis. Age and gender are also important factors for the market.
The incidence rates of the disease are higher in females than in males. The market is witnessing significant growth due to increasing awareness about the disease and the rise in cases. The key factor supporting this growth is the development of new dengue vaccines and the rising preference for preventive measures among consumers.
This is mainly due to increasing awareness about the disease and its negative effects and increased funding for research and development of new vaccines. As a result, the market is expected to be worth $7.8 billion by 2028, growing at a CAGR of 7.1% during the said period.
Some of the factors that are expected to propel growth in the dengue vaccine market include increasing incidence of dengue cases, rising demand from emerging markets such as India and China, and uptake of preventive measures such as prophylactic vaccinations by patients. As a result, the Asia-Pacific region is expected to account for the largest market share in terms of revenue during 2022-2028, followed by North America and Europe.
The global dengue vaccines market is a highly competitive landscape. It is characterized by high prevalence rates of the disease in urban areas. The World Mosquito Program has stated that a rising population in urban areas will increase the rate of dengue infections by 40% in the next five decades. However, this scenario is a major challenge for the vaccines market.
The global dengue vaccines market is expected to reach USD million by 2027. It is projected to grow at a CAGR of % from 2022 to 2027. The report provides details on the market by type, application, and company. The study has high data integrity. The global dengue vaccines market data is validated with reliable sources to ensure the accuracy of the statistics and predictions.
In addition to the two approved vaccines, there are several other products in clinical trials. The Sanofi vaccine, TAK-003, has the highest market share. Other products include Covid19 Anal, Dengvaxia, and other products. The company that has the highest market share amongst these four drugs is the leader in the field of dengue vaccinations.
The government institutes segment is expected to grow steadily, leading to lucrative gains for the companies in the market. Furthermore, the increasing incidence of dengue is predicted to lead to a growing number of vaccines. The report will also identify the major challenges, trends, and opportunities for the industry. There are various segments in the market.
The dengue vaccine market will reach USD million by 2027, with a CAGR of % during the forecast period. The global market for dengue vaccines is divided into different regions. Each region is detailed in the report to highlight growth opportunities in the dengue vaccines market. The regional markets are based on the country and the disease-specific type.
Final Words
The market is likely to be driven by the increasing incidence of dengue, rising awareness about dengue vaccines, and the launch of new vaccines. The analysis of Covid-19 provides a deeper understanding of the dynamics of the Dengue Vaccines Market and will help stakeholders make informed decisions about the future of this market.
